Apellis Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Apellis Pharmaceuticals, Inc.
Danicopan seen as potential add-on therapy for paroxysmal nocturnal hemoglobinuria patients getting suboptimal results from Soliris or Ultomiris therapy. AstraZeneca will investigate filing for approval on 12-week data.
The company plans to file the complement C5 inhibitor with the US FDA, but Apellis already has a drug pending for the indication.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
The Swedish rare disease specialist has expanded its hematology franchise by getting the European rights to ADC Therapeutics’ Zynlonta, which has yet to make much impact commercially in the US.